Taysha Gene Therapies, Inc. recently released its 10-Q report, providing detailed insights into the company's financial condition and operations. The clinical-stage biotechnology company is focused on developing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. Its lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The company has completed dosing of 10 patients in Part A of both REVEAL trials, with TSHA-102 being generally well tolerated and showing no treatment-related serious adverse events.
In the 10-Q report, Taysha Gene Therapies disclosed its financial condition, stating that it has funded its operations primarily through equity sales, private placements, and loan agreements. As of March 31, 2025, the company had an accumulated deficit of $623.8 million and incurred a net loss of $21.5 million for the three months ended March 31, 2025. Taysha Gene Therapies anticipates incurring significant expenses and operating losses for the foreseeable future as it continues to advance the clinical development of its product candidates and seeks regulatory approval for any successful candidates.
The company also provided an overview of its pipeline, highlighting its focus on discovering, developing, and commercializing gene therapies for the treatment of monogenic diseases of the CNS. Taysha Gene Therapies emphasized its commitment to addressing severe unmet medical needs and improving the lives of patients and their caregivers through transformative medicines.
Furthermore, the 10-Q report detailed the company's license agreements, including a research, collaboration, and license agreement with The University of Texas Southwestern Medical Center, as well as a license agreement with Abeona Therapeutics Inc. for the prevention, treatment, or diagnosis of CLN1 Disease in humans.
Today the company's shares have moved 1.28% to a price of $2.37. For more information, read the company's full 10-Q submission here.
